Acasti Pharma Inc. (ACST) Wednesday reported fourth-quarter loss of $1.95 million or $0.03 per share, up from $1.55 million or $0.02 per share in the prior-year quarter.
Revenues improved to $49 thousand from $10 thousand last year, with sales coming entirely from the commercialization of Onemia.
Research and development expenses increased to $918 thousand from $387 thousand last year.
For comments and feedback: editorial@rttnews.com